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ABSTRACT
Tissue-/cancer-specific promoters for use in adeno-
virus vectors (AdVs) are valuable for elucidating
specific gene functions and for use in gene
therapy. However, low activity, non-specific expres-
sion and size limitations in the vector are always
problems. Here, we developed a ‘double-unit’ AdV
containing the Cre gene under the control of an
a-fetoprotein promoter near the right end of its
genome and bearing a compact ‘excisiona-
l-expression’ unit consisting of a target cDNA
‘upstream’ of a potent promoter between two
loxPs near the left end of its genome. When Cre
was expressed, the expression unit was excised as
a circular molecule and strongly expressed.
Undesired leak expression of Cre during virus prep-
aration was completely suppressed by a dominant-
negative Cre and a short-hairpin RNA against Cre.
Using this novel construct, a very strict specificity
was maintained while achieving a 40- to 90-fold
higher expression level, compared with that attain-
able using a direct specific promoter. Therefore,
the ‘double-unit’ AdV enabled us to produce a
tissue-/cancer-specific promoter in an AdV with a
high expression level and strict specificity.
INTRODUCTION
Because tissue-speciﬁc promoters enable us to express a
gene in a cell-type-speciﬁc manner in vivo or in a
primary tissue culture, such promoters offer an attractive
approach to studying the speciﬁc functions of a gene
product in the tissues of experimental animals, such as
in the brain where cells of different types are present
together in the same region. The use of transgenic/
knockout mice and adenovirus vectors (AdVs) are the
most common approaches for utilizing these promoters.
Among such promoters, those speciﬁc to malignant cells
may be valuable for speciﬁc gene therapy or the diagnosis
of cancer.
However, one drawback of such promoters is that their
expression levels are much lower than those of a versatile
promoter, such as the cytomegalovirus (CMV)
immediate-early, CAG (1) or EF1a (2) promoters. For
example, the a-fetoprotein (AFP) promoter, which is a
relatively strong promoter among tissue-speciﬁc pro-
moters, is reported to be  500-fold less active than the
CAG promoter (3), limiting its usefulness. Another im-
portant problem associated with the use of these pro-
moters is that their speciﬁcity was often not sufﬁciently
strict. One possible reason is that the excised segment of
a speciﬁc promoter lacks the sufﬁcient control of speciﬁc
silencers and shows some ‘basal level’ of expression. In
some cases, the lack of speciﬁcity might arise from the
DNA elements surrounding the promoter, rather than
the intrinsic character of the speciﬁc promoter (4,5). In
human gene therapy using AdV, a strict speciﬁcity is
critically important for safety as well as efﬁcacy.
As one solution, we previously reported a
‘double-infection’ method (3), in which the virtual
activity of AFP promoter was increased by about
50-fold while maintaining a strict speciﬁcity. With this
method, two AdVs are infected simultaneously: one
AdV contains a ‘switch unit’ consisting of Cre gene
under the control of AFP promoter, and the other AdV
bears a ‘target unit’ consisting of the CAG promoter,
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cDNA, in that order. In non-hepatocarcinoma cells, the
expression of the reporter cDNA remains turned off.
However, in target hepatocarcinoma cells, AFP
promoter in the switch unit of one AdV is turned on,
leading to the production of Cre enzyme; this in turn
leads to the excision of the stuffer sequence in the other
AdV by Cre-mediated site-speciﬁc recombination, leaving
the CAG promoter and the target gene connected only
through a loxP sequence and enabling the strong expres-
sion of the target gene. Even when AFP promoter is weak
and only a small quantity of Cre protein is produced, Cre
can act as an enzyme multiple times, allowing most of the
target AdV genomes to be processed eventually and ac-
counting for the very high level of expression that can be
obtained. The double infection method has been applied
in numerous in vivo studies examining gene therapy for
lung, colon and gastric cancers using the
carcinoembryonic antigen promoter (6–10), for thyroid
cancer using the thyroglobulin promoter (11), for
hepatocellular carcinoma using AFP promoter (12), for
prostate cancer using the prostate-speciﬁc antigen
promoter (13) and for astrocytoma using the
astrocytoma-speciﬁc promoter for GFAP (14). The
method has also been applied in brain research using a
modiﬁed, neuron-speciﬁc promoter of superior cervical
ganglion 10 (15).
However, because the double-infection method uses two
different AdVs simultaneously, controlling the infection is
complicated and not often reproducible. Additionally, the
toxicity and inﬂammation are at least doubled, compared
with a single viral infection, for transducing the same
amount of the target unit. Moreover, since a single cell
infected with only one of the vectors does not produce any
target protein, many such cells remain unused, causing a
low expression as a result of dilution (12). Therefore, as a
simpler, safer and more effective vector, an AdV bearing
both the switch and the target unit simultaneously in a
single genome is needed. However, the development of
such an AdV has been regarded as being very difﬁcult,
since the sum of the lengths of both units exceeds the
maximum length of the AdV genome. Furthermore, a
leak in the expression of Cre can produce a large
amount of stuffer-lacking AdV during vector preparation,
causing severe non-speciﬁc expression. In addition, an
enhancer of the potent promoter in the target unit may
decrease the speciﬁcity of the speciﬁc promoter in the
switch unit. Thus, a new vector is needed to solve these
problems.
Here, we report the development and successful prep-
aration of an AdV containing both units in a single
genome. The vector, called a ‘double-unit’ AdV, possesses
an extraordinary ‘excisional-expression’ structure and
solves the aforementioned problems simultaneously,
because the target unit of this vector lacks a stuffer
sequence and because the target gene is expressed
not from its genome, but from an excised circular
DNA. The developed AdV shows a high level of expres-
sion (40- to 90-fold) while maintaining a very strict
speciﬁcity.
MATERIALS AND METHODS
Cells and AdVs
The human embryo kidney cell line, 293 (16), constitu-
tively expresses adenoviral E1 genes and supports the rep-
lication of E1-substituted AdV. HepG2 (17) and HuH7
(18) cells are human hepatocellular carcinoma cell lines
that produce AFP. SK-Hep-1 (19) cells are a human
hepatocellular carcinoma cell line that lack AFP produc-
tion. HeLa cells, derived from cervical cancer, do not
express AFP (20). The cell line CV1 is derived from
African green monkey kidney. The AFP promoter
used here was the (AB)2S6 AFP promoter (3). The
EF1a promoter has been described previously (2).
AxA2ANCre was described previously (3). AxLR14EL-
AC, AxLR16EL-AC, AxLR16EFL, Ax-AC, AxNZ,
AxLNZCAL, AxALNZCAL, AxA2AdsR and AxEFdsR
are described for the ﬁrst time in this work. AdVs
described here were constructed using cosmid transfection
(21). All the aforementioned viruses except for
AxA2AdsR and AxEFdsR possessed E3 region with a
2.4-kb deletion, while the latter two viruses bore E3
region with the 1.9-kb deletion described in reference
(21) (see ‘Discussion’ section). The switch unit was
inserted at the SnaBI site (nt position 35770), located
165-nt downstream from the right end of the adenovirus-5
(Ad5) genome. Because the standard Ad5 genome does
not contain the SnaBI site, we generated a restriction
site using nucleotide substitution, inserted a SwaI linker,
and then cloned the switch unit. All the viruses were
puriﬁed using a CsCl step gradient (22) and titrated
using a method measuring 50% tissue culture infectious
dose (TCID50) (22); the viral particle: TCID50 ratio was
 20:100, including double-unit viruses. The viral titer of
all the AdV, including double-unit vectors was measured
with TCID50 using normal 293 cells.
Dominant negatives and shRNAs of Cre and isolation of
Cre-suppressed 293 cells
dnCreRY was a dominant negative of Cre, where Arg173
and Tyr324 were mutated to Ala and Phe, respectively.
pyCANCRYit2 is a plasmid expressing dnCreRY under
the control of CAG promoter. The dnCreRY cDNA was
excised as a SmaI-BglII fragment and inserted into
pTrcHis2A (Invitrogen) between the Ecl36II and BglII
sites under the Escherichia coli trc promoter (23).
The BssSI-SphI fragment containing trc-dnCreRY was
transferred upstream of the cos site of cosmid
pAxLR16EL-AC and pAxLR14EL-AC, which were
both derived from pAxcwit2 (21). The resulting cosmids
were named ptdC-AxLR16EL-AC and ptdC-AxLR14EL-
AC, respectively. shCreD (TA0493-4-D) was an shRNA
of Cre, gatccGAAGCAACTCATCGATTGAtagtgctcctg
gttgTCAATCGATGAGTTGCTTCtttttta (Cre sequences
are in capitals), which efﬁciently suppressed Cre activity.
TA0493-4-D was inserted under the human U6 promoter
of plasmid pBAsi hU6 Pur (Takara Bio). The
293dnCreRY8 and 293shCreD13 were the best cell lines
containing dnCreRY under the control of CAG promoter
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Cre activity among those tested, respectively.
To generate 293dnCreRY8, pBCANCRYSAPur
was constructed, expressing dnCreRY under the control
of the CAG promoter and the puromycin-resistant
(Pur
R) gene under the control of the SV40 early
promoter (Figure 5a). To generate 293shCreD13,
pBSAPurhU6shCre was constructed, expressing one of
the short-hairpin (sh) RNAs against Cre under the control
of the human U6 promoter (Takara Bio) and the Pur
R
gene identical to that expressed by pBCANCRYSAPur
(Figure 5b). Ten micrograms of each plasmid DNA were
transfected into 293 cells using Transfast
R (Promega). Two
days after transfection, puromycin was added at a concen-
tration of 2.5mg/ml. We selected the cell line that
most efﬁciently caused a reduction of Cre activity for the
simultaneous transfection in Cre-expressing and target
pCALNLG plasmids (24).
Preparation of total cell DNA for restriction-enzyme
digestion and for real-time PCR
Infected cell DNA was prepared on a 24-well plate as
previously described (25) with some modiﬁcations: the
cells were suspended in 0.4ml of TNE-PK [50mM Tris–
HCl (pH 8), 100mM NaCl, 10mM EDTA, 100mg/ml
proteinase K], followed by the addition of SDS (ﬁnal
0.1%). After incubation at 55 C for 2 h, the mixture was
extracted once with phenol–chloroform and once with
chloroform, and precipitated with 1 or 1.5 volumes of
ethanol at  20 C for >1h and then washed once with
70% ethanol. The pellet was dissolved with 50ml of TE
containing 20mg/ml RNase A and stored at  20 C. This
DNA was sufﬁcient not only for real-time PCR but also for
gel electrophoresis to observe the structure of the AdV
genome.
To detect viral DNA, total DNA extracted from
AxLR16EL-AC-infected, Cre-suppressed 293 cells in a
24-well plate was digested with BmgBI. The BmgBI recog-
nition sequence, CACGTG, contains a -CG- dinucleotide,
which is mostly methylated in the mammalian genome and
cannot be cleaved by a restriction enzyme, while
replicating adenoviral DNA is not methylated and can
be cleaved. Consequently, restricted patterns of only
adenoviral DNA can be seen.
Quantiﬁcation of AdV transduction efﬁciency and
expressed RNA
Total cell DNA was prepared as described above.
Real-time PCR was performed to detect the adenovirus
genome using a probe for the pIX gene, and human
chromosome was simultaneously detected using a probe
for the b-actin gene or the ornithine transcarbamylase
(OTC) gene. The threshold cycle (cT) values were
obtained. All the probes used in the study are shown in
Table 1. The cT value of the AdV was corrected according
to that for the human chromosome probe. The sequences
of these probes were shown in Table 1. Infected cell RNA
was prepared using the RNeasy protect mini kit (Qiagen)
according to the manufacturer’s protocol. To prepare the
cDNA, the TaqMan Reverse Transcriptase Reagent kit
(Applied BioSystems) was used. The sequences of the
dsRed probes are shown in Table 1. The 18S rRNA
primer used in the study were Ribosomal Eukaryotic
18S rRNA kit (Applied BioSystems).
To examine the expressed dsRed RNA, the cells were
infected with AdV and total DNA and the total RNA was
extracted. From the total DNA, the amounts of AdV
genome and b-actin gene were simultaneously quantiﬁed
using real-time PCR and the ratio of AdV genome per cell
was obtained. Similarly, from the total RNA, the amounts
of dsRed RNA and 18S-rRNA (the correction standard)
were quantiﬁed using reverse transcription and real-time
PCR, and the ratio of dsRed RNA to 18S-rRNA was
obtained. Based on these results, the ratio of the dsRed
RNA level between the two cell lines was calculated.
Detection of expressed ﬂuorescence
To evaluate the different EF1a promoter versions, the cells
were washed twice with Hank’s balanced salt solution
3 days after transfection, and the intensity of GFP ﬂuores-
cence was quantiﬁed using Fluoroskan Ascent FL
(Labsystems) (26). Cells infected with AxLR16EL-AC
and AxLR14EL-AC were sorted using dsRed ﬂuorescence
using FACS (FACSCalibur, Becton-Dikinson). The dsRed
ﬂuorescence was also measured using Ascent ﬂuorescent
meter. To calculate the relative strengths among the
various promoters, the steady-state level of the expressed
dsRed RNA together with the dsRed DNA in the AdV
genome in infected cells was quantiﬁed using a real-time
PCR (Prism 7000, Applied Biosystems), and the former
value was divided by the latter.
RESULTS
Structure of ‘double-unit’ vector containing
‘excisional-expression’ unit
The structure of the ‘double-unit’ AdV vector
AxLR16EL-AC is shown in Figure 1. This vector is a
Table 1. Sequences of probes used in real-time PCR
Probe
a Primer sequences
b
AdV-1 F: TGTGATGGGCTCCAGCATT
P: ATGGTCGCCCCGTCCTGCC
R: TCGTAGGTCAAGGTAGTAGAGTTTGC
hOTC-1 F: CCACTACAAAATAAAGTGCAGCTGAA
P: CCGTGACCTTCTCACTCTAAAAAACTT
R: CTGATAGCCATAGCATATATTTAATTTCTTCTC
b-Act-1 F: CTCGCAGCTCACCATGGAT
P: ATGATATCGCCGCGCTCGTCGT
R: ATGCCGGAGCCGTTGTC
dsRed-1 F: GCAGCTGCCCGGCTACT
P: CGTGGACTCCAAGCTGGACATCACCT
R: CGATGGTGTAGTCCTCGTTGTG
18S rRNA primers used were Ribosomal Enkaryotic 18S rRNA kit
(Applied BioSystems).
aName of the probes. Reporters used were FAM except b-Act-1 (VIC
reporter).
bF, forward primer; P, probe; R, reverse primer. Real-time PCR was
purchased from Applied BioSystems.
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near the right end of the adenovirus genome (27)
(denoted in this paper at the E4 position) and the target
unit inserted in the E1 region. Since the adenovirus genome
can be packaged into a capsid up to  105% of, or 2kb
morethan,thewild-typegenomesize(28),itwasimpossible
to generate an AdV containing both the switch and the
target units using a typical construction strategy because
of over-sizing. Therefore, to shorten the total length of the
units, an ‘excisional-expression’ structure was adopted for
the target unit. Although a typical target unit for condi-
tional expression possesses (in order) the potent promoter,
loxP, a stuffer sequence, a second loxP, cDNA and
polyadenylation sequences (poly(A)), the excisional-
expression unit lacks a stuffer sequence and instead
consists of (in order) the right loxP, dsRed cDNA,
poly(A), EF1a promoter and the left loxP (Figure 1,
Target unit on AxLR16EL-AC). Notably, the dsRed
cDNA is located not downstream, but ‘upstream’ of the
EF1a promoter and, therefore, dsRed expression is
turned off in the initial structure because AFP promoter
does not function in non-hepatocarcinoma cells. However,
once the AdV infects a hepatocarcinoma cell, AFP
promoter is turned on and Cre enzyme is produced.
Consequently, the expression unit of dsRed—EF1a
promoter with one loxP is ‘excised’ as a circular molecule
(Figure 1, middle), and the dsRed cDNA is now located
downstream of the EF1a promoter, turning its expression
on. At the same time, an AdV genome with one loxPi s
produced (Figure 1, lower, AxL-AC).
To minimize the genome size of the double-unit AdV:
(i) a 0.55-kb section of the E3 region was deleted (see
‘Discussion’ section). In addition (ii) the EF1a promoter
was shortened from an original length of 2.1kb to lengths
of 1.6 and 1.4kb (named 16EF and 14EF, respectively).
Unexpectedly, both the 16EF and 14EF promoters
showed higher activity levels than the original EF1a
promoter (Figure 2). As well; (iii) the 0.6-kb rabbit
b-globin poly(A) sequence was truncated to 0.3kb up to
NdeI site. In addition to the size limitation, the
double-unit AdV possesses several features that enable a
very strict speciﬁcity (see Discussion section). As an im-
provement, the poly(A) sequence of 137nt derived from
the SV40 early region (HpaI-BamHI) was added in front
of the dsRed cDNA plus the right loxP on the target unit
(Figure 1, upper) based on the results of the following
experiments. We constructed three AdVs containing the
lacZ DNA tagged with the nuclear localization signal
[NLacZ (3)] and their structures are shown in Figure 3a.
CV1 cells were infected with each of these AdVs at multi-
plicity of infection (MOI) of 50 and, three days later,
the lacZ expression of the infected cells was detected
with X-gal staining. When cells were infected with
AxNZ containing promoterless NLacZ (Figure 3a, top),
weak but signiﬁcant background expression was observed
in most of the cells (Figure 3b, lower left); such expression
was not observed in mock-infected cells (Figure 3b, upper
left). When cells were infected with AxLNZCAL contain-
ing an excisional expression unit lacking the poly(A) in
front of the NLacZ plus loxP (Figure 3a, middle), signiﬁ-
cant expression was observed (Figure 3b, upper right) and
the expression level was much higher than that using
AxNZ (lower left). We speculate from these results that
a weak cryptic promoter may present upstream of the
NLacZ and be activated by the enhancer of CAG
promoter downstream of the NLacZ. Nevertheless, using
AxALNLZCAL containing the excisional expression unit
possessing poly(A) in front of NLacZ DNA plus loxP
(Figure 3a, bottom), the background expression was
almost disappeared (Figure 3b, lower right). The result
showed that the inserted poly(A) sequence effectively
reduced the background expression. The results were con-
ﬁrmed in the transfection experiments using the cosmids
containing the full-length AdV genome (data not shown).
Finally, we attempted to construct two AdVs,
AxLR16EL-AC (104.9% of wild-type adenovirus
genome) and AxLR14EL-AC (104.4%) containing the
16EF and 14EF promoters, respectively. The genome
sizes of both AdVs were under the size limit.
Leak expression of Cre both in E. coli and in 293 cells
hampers the preparation of double-unit AdVs
Unexpectedly, during the construction of cosmids con-
taining either AxLR16EL-AC or AxLR14EL-AC DNA
(Figure 4a, dnCreRY –), we observed the co-generation
of cosmids lacking the sequences between the two loxPs
(Figure 4b). The 2.5- and 2.7-kb bands (Figure 4c, lane 3)
showed the presence of both cosmid DNA containing the
AxL-AC genome and the excised circular DNA molecule,
respectively. Judging from the intensities of the bands, the
AxL-AC DNA accounted for  15–20% of the midi-
preparation (23) of E. coli. Thus, Cre must be expressed
during cosmid preparation in E. coli DH5a despite the
absence of an obvious E. coli promoter in the cosmid:
the ampicillin promoter was present, but in the opposite
orientation and  20kb away. Although the AxL-AC
cosmid DNA was detected only faintly in the DNA of
Figure 1. Structure of double-unit AdV and generation of expressing
circular DNA. L, loxP; 16EF, shortened EF1a promoter; pA, poly(A)
sequence; dsR, dsRed cDNA; AF, AFP promoter; Cre, nuclear
localization signal-tagged Cre cDNA.
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over time.
Furthermore, after the transfection of the cosmid DNA
containing AxLR16EL-AC into 293 cells, all 12 of the
viral clones that were generated were not the target
virus, but apparently an AxL-AC virus. And three out
of 18 viral clones derived from AxLR14EL-AC-containing
cosmid DNA were mixtures of AxLR14EL-AC and AxL-
AC viruses, while the other 15 clones were apparently pure
AxL-AC virus (data not shown). These results showed
that AFP promoter, which is thought to be inactive in
non-hepatocellular 293 cells, certainly produced Cre in
an amount sufﬁcient to recombine the loxPs on the AdV
genome. This result probably occurred because even if the
AFP promoter was strictly regulated, the AdV genome
containing the switch unit of AFP promoter and Cre
was ampliﬁed for 100000 copies in one 293 cell and, con-
sequently, an effective amount of Cre would be produced.
Therefore, because of the leakage of Cre expression in
both E. coli and 293 cells, double-unit vectors could not
be prepared using conventional methods.
Successful suppression of leak expression of Cre using a
dominant-negative of Cre and shRNA against Cre
To suppress the leak expression of Cre in E. coli, several
dominant-negatives of Cre containing two amino acid
mutations at the active center of Cre enzyme were con-
structed; dnCreRY, the dominant-negative that most efﬁ-
ciently suppressed Cre activity among those tested in
co-transfection assays with a target plasmid, was then
selected. Next, we constructed an expression unit
producing dnCreRY under the control of the trc
promoter of a lac operon system, and this unit was
inserted into the cosmids containing AxLR16EL-AC and
AxLR14EL-AC DNAs (Figure 4a, dnCreRY +). In the
midi-preparation of this AxLR16EL-AC cosmid, neither
the recombined AxL-AC-derived band nor the excised
circular DNA molecule was detected with IPTG induction
(Figure 4c, lane 7), showing that the production of
dnCreRY successfully suppressed the leak expression of
Cre in E. coli. Interestingly, since an apparent complete
suppression was also observed without IPTG induction
(lane 6), dnCreRY produced by the basal activity of the
trc promoter was sufﬁcient to suppress the leak expression
of Cre effectively. Therefore, the problem of the leak
expression of Cre in E. coli was solved.
To suppress the leak expression of Cre during AdV
preparation in 293 cells, a plasmid expressing dnCreRY
and a puromycin-resistant (PurR) gene (Figure 5a, upper)
was transfected into 293 cells and the cell line
293dnCreRY8 was established; this cell line suppressed
Cre activity the most efﬁciently. Virus clones were
Figure 2. Expression of truncated EF1a promoter. (a) Structure of the plasmids expressing GFP under truncated EF1a promoter. The original EF1a
promoter is 2.1-kb long. The 50-end of 16EF was the PpuMI site and that of 14EF was the BlpI site. (b) Images obtained using ﬂuorescent
microscopy. (c) Fluorescence measured using a ﬂuoroscan plate reader. Vertical axis showed ﬂorescence in arbitrary unit; n=4.
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and the digestion of the viral genome with BmgBI yielded
a 1.8-kb band from an intact AxLR16EL-AC virus and a
1.4-kb band from a processed AxL-AC virus (Figure 5c).
The 293dnCreRY8 cells did not produce pure
AxLR16EL-AC virus, but instead produced mixtures of
AxLR16EL-AC and AxL-AC (Figure 5a, lower, lanes 1,
3, 4 and 6) or mostly AxL-AC (lanes 2 and 5). Therefore,
the suppression of Cre activity in the 293dnCreRY8 cells
was not complete.
Meanwhile, several sh RNAs against Cre were con-
structed and screened, and shCreD was identiﬁed. Then,
a plasmid expressing shCreD and PurR (Figure 5b, upper)
was transfected into 293 cells, and the cell line
293shCreD13 was established. Unlike 293dnCreRY8,
293shCreD13 yielded mostly viral stocks of apparently
pure AxLR16EL-AC virus (Figure 5b, lower, lanes 2, 3,
4 and 5), though some stocks were mixtures of both
viruses (lanes 1 and 6). The AxLR16EL-AC virus in the
apparently pure stocks was ampliﬁed in 293shCreD13
cells. To examine the ‘leaky’ expression level of Cre
during the production of the double-unit vector in
293shCreD13 cells, an aliquot of AxLR16EL-AC viral
stock was used to infect 293shCreD13 cells; then, to
detect the viral genome, the total cell DNA was digested
with BmgBI. The 1.4-kb band produced by Cre recombin-
ation was not detected up to and including the third stock
(data not shown) but, when the fourth stock puriﬁed using
CsCl ultracentrifugation was examined, observed were the
bands showing that the ratio of intact AxLR16EL-AC
and ‘leaked’ AxL-AC was  10:1 (Figure 5b, lower
right). Of note, contamination with the AxL-AC virus
does not cause any non-speciﬁc expression because
Cre-processed AxL-AC virus does not contain an expres-
sion unit (Figure 1, bottom). An important point is that to
prepare a double-unit AdV, the selection of an apparently
Figure 4. Leak expression of Cre in E. coli. Representations are the same as in Figure 1 unless otherwise stated. (a) Structure of cosmid generating
double-unit AdV and expressing dnCreRY. , adenovirus packaging sequences; P trc, trc promoter; t, terminator. (b) Generation of Cre-processed
molecules. A, AhdI site. (c) Detection of Cre-processed molecules. M, 1-kb ladder marker; mn, mini-preparation; md; midi-preparation. The bands of
2.7 and 2.5kb represent the generated circular DNA and Cre-processed DNA, respectively.
Figure 3. Suppression of the background expression by adding poly(A)
sequence in front of lacZ DNA. (a) Structure of AdVs. (top) AxNZ
contains the promoterless lacZ DNA; (middle) AxLNZCAL contains
the excisional expression unit lacking poly(A) sequence in front of lacZ
DNA plus right loxP; (bottom) AxALNZCAL contains that unit pos-
sessing poly(A) sequence in front of lacZ DNA plus right loxP. NlacZ,
lacZ DNA tagged with NLS; , adenovirus packaging sequences;
CAG, CAG promoter. The other representations are the same as in
Figure 1. (b) Reduction of the ‘background’ expression observed using
the promoterless lacZ DNA caused by addition of the poly(A)
sequence. The infected CV1 cells were stained by X-gal. Very few
dark-stained cells were observed in panels AxNZ (lower left) and
AxALZCAL (lower right); the origin of these cells were unknown
but possibly similar to those observed in Figure 7b and e.
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Figure 5b, lower left, may be essential (see ‘Discussion’
section).
The 293shCreD13 cells grew well, similar to normal 293
cells, and the double-unit viruses were apparently able to
proliferate in 293shCreD13 cells as well as normal
E1-deﬁcient AdV in 293 cells. Table 2 shows the titers of
the double-unit virus AxLR16EL-AC produced in
293shCreD13 cells and of the split viruses shown in
Figure 7a produced in normal 293 cells, all of which
were used in this work. The titer of the double-unit virus
was sufﬁciently high, though it was lower than those of the
split viruses. One possible reason may be that the genome
size of the former is near the upper limit. The
AxLR14EL-AC virus was similarly prepared, and
AxL-AC virus contamination was not detected in the
third stock (data not shown).
The third viral stocks of double-unit virus without CsCl
puriﬁcation produced low but not negligible levels of
non-speciﬁc dsRed expression when infected in HeLa
cells (data not shown). Importantly, however, a viral prep-
aration that was puriﬁed using a CsCl step gradient (22)
did not produce any non-speciﬁc expression (see
‘Discussion’ section). Therefore, double-unit AdVs
prepared in 293shCreD13 and puriﬁed using a CsCl
step-gradient enabled the creation of viral stocks with a
very strict speciﬁcity.
High-efﬁciency and very strict expression using
double-unit AdV
The AxLR16EL-AC virus (at MOI of 5) was used to
infect various cell types including HeLa (derived from
non-liver carcinoma), SK-Hep1 (hepatocarcinoma-
derived, non-producer of AFP), HuH-7 and HepG2
(hepatocarcinoma-derived producer of AFP). On day 3,
high-level expressions of dsRed were observed in the
infected HuH-7 and HepG2 cells (Figure 6h and k).
Fluorescence-activated cell sorter (FACS) analyses
showed that  86 and 92% of these cells expressed detect-
able levels of dsRed, respectively (Figure 6i and l). In
contrast, only one or two cells in a ﬁeld of HeLa or
SK-Hep1 cells expressed detectable levels of dsRed
(Figure 6b and e), showing that the expression speciﬁcity
of this vector was very strict. The FACS analyses
conﬁrmed that only 0.7 and 0.5% of the respective cells
expressed detectable dsRed (Figure 6c and f). The results
of dose-dependent experiments for all four cell lines
conﬁrmed the speciﬁcity of expression (Supplementary
Figure S1).
Figure 5. Establishment of 293 cell lines suppressing Cre activity. (a) Structure of plasmids expressing dnCreRY (upper) and DNA restriction
pattern of double-unit viral clones produced in 293dnCreRY8 cells (lower). CA, CAG promoter; SV, SV40 early promoter; Pur
R,
puromycin-resistant gene. The other representations are the same as in Figure 1. M, 1-kb ladder marker; c, restriction pattern of
AxLR16EL-AC-containing cosmid DNA, presenting as a 1.8-kb band. (b) Structure of plasmids expressing shCre (upper) and DNA-restriction
pattern of double-unit virus DNA of double-unit viral clones produced in 293shCreD13 cells (lower). hU6, human U6 promoter. P, puriﬁed/fourth
stock was infected. The other representations are the same as in (a). (c) Generation of AxL-AC. B, BmgBI site. The other representations are the
same as in Figure 1. The presence or absence of circular 2.7-kb DNA was not clear in the gels of (a) and (b) because of the viral-derived bands of 2.9,
2.7 and 2.6kb, but the circular DNA was hardly detected in the other experiment (data not shown). This result suggests that the production of the
circular molecule occurs just after transfection and is consistent with the result that AxLR16EL-AC was stable up to the fourth stock.
Table 2. The viral titers of double-unit virus and the sprit viruses
Viruses
a Cells Titers
b (TCID50)
AxLR16EL-AC 293shCreD13 1.1 10
10
AxLR16EL Normal 293 4.7 10
11
Ax-AC Normal 293 7.6 10
10
aThe structure of AxLR16EL-AC is shown in Figure 1. The structures
of split viruses, AxLR16EL and Ax-AC were shown in Figure 7a.
bForth, puriﬁed viral stocks used in all experiments in this work.
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measuring the total sum of all cell ﬂuorescence. The
results showed that the ratio of the expressed mean ﬂuor-
escence among the HeLa:SK-Hep1:HUH-7:HepG2 at
MOI 5 in Figure 6c, f, i and l was 0.7:1:36.6:77.4,
showing that the level of ‘leaked’ expression in the total
cell population of AFP-negative cells compared with that
in the AFP-positive cells was  40 to 80 times less.
The results of dose-dependent experiments are shown in
Figure 6m. These results showed a very high expression
and a strict speciﬁcity of this vector. Parallel to these
FACS experiments, the transduction efﬁciency of the
AdVs was measured by examining aliquots of all the
four cell lines using real-time PCR as described in
‘Materials and methods’ section. The results indicated
that the ratio of transduction efﬁciencies among HeLa,
SK-Hep1, HuH-7 and HepG2 were 1.3:1:1.2:7.6,
showing that the number of transduced AdV genomes
present was almost the same for the ﬁrst three cells.
Therefore, these results conﬁrmed very strict speciﬁcity
of this vector for HeLa and SK-Hep1 cells. Meanwhile,
HepG2 cells reproductively showed exceptionally high
transduction efﬁciency. This seemed to be associated
with the result that HepG2 showed much higher expres-
sion levels than HuH-7 cells (Figure 6m, at MOIs 1.7 and
5). Therefore, the very high expression level of HepG2 was
partly explained by its exceptionally high transduction
efﬁciency.
To examine the speciﬁcity of the double-unit vector,
total RNA and DNA were extracted from
AxLR16EL-AC-infected SK-Hep1 (AFP-negative) and
HuH-7 (AFP-positive) cells. The amounts of expressed
Figure 6. Speciﬁc and high-level expression of dsRed by AFP promoter using double-unit virus. Cells were infected with AxLR16EL-AC at MOI 5.
(a–c) HeLa; (d–f) SK Hep-1; (g–i) HuH-7; (j, k and l) HepG2. (a, d, g and j) Phase-contrast microscopic views. (b, e, h and k) Images obtained using
ﬂuorescent microscopy. The arrow heads show exceptional cells with non-speciﬁc ﬂuorescence. (c, f, i and l) FACS analysis of dsRed-expressing cells.
SSC-H, side scattered light, high ﬂow rate. (m) Dose responses of dsRed expression in the infected cells.
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measured using real-time PCR as described in the
Materials and methods section. The ratio of the dsRed
RNA level corrected according to the transduced AdV
genome between the two cell lines was calculated. The
result showed that the dsRed RNA ratio of HuH-7 and
SK-Hep1was 42.0:1, correlating well with the quantiﬁca-
tion of dsRed expression using FACS analyses. Identical
experiments were performed using a control AdV
AxCAdsRed expressing dsRed under the control of the
CAG promoter instead of the double-unit vector. The
result showed that the RNA ratio corrected according to
the viral DNA amount between HuH-7 and SK-Hep1was
1.38:1, indicating that the activity of the CAG promoter
was similar in both cell lines. These results indicated that
the ‘leak’ level of the double-unit vector in the SK-Hep1
cells, compared with that in the HuH-7 cells, was  1/40th
of the expression level of HuH-7 cells (or 1/30th, based on
of the CAG promoter control), demonstrating that the
background level of double-unit vector in AFP-negative
cells was again very low.
To examine the effect of combining the switch unit and
the target unit into a single genome, we newly constructed
two AdVs: AxLR16EL, containing only the target unit
(Figure 7a, ﬁrst), and Ax-AC, containing the switch unit
at the E4 position (Figure 7a, second), as in AxLR16EL-
AC. Then, the expression of the double-unit vector
(AxLR16EL-AC) and the double infection of split
viruses containing the excisional expression unit
(AxLR16EL+Ax1AC) was examined using dsRed ﬂuor-
escence. The double-unit vector showed a much higher
ﬂuorescence level than the double-infection method, as
observed under a ﬂuorescent microscope (Figure 7b).
And the quantitative measurement of dsRed ﬂuorescence
showed that the former method produced 3.3-fold more
dsRed protein than the latter method using an MOI of 13
(Figure 7c). The reason that the expression level was
higher than that of the split viruses appears to be not
only because the amount of the target virus was one half
of the same total dose of the viruses, but also because in
many cells, the split two vectors were not infected simul-
taneously or did not produce a sufﬁcient amount of Cre
during ﬁve days.
The steady-state levels of expressed dsRed RNA
measured using real-time PCR in HuH-7 cells were
compared with the direct expression under the control of
AFP promoter (AxA2AdsR, Figure 7a), a double-unit
vector (AxLR16EL-AC), a double-infection of split
viruses (AxLR16EL+Ax-AC), and the expression under
the control of EF1a promoter (AxEFdsR, Figure 7a)
(Table 3). On Day 3, the double-unit vector expressed
 40-fold more dsRed RNA than the direct expression
under the control of AFP promoter. Meanwhile, the
double infection of split viruses (AxLR16EL+Ax-AC) ex-
pressed dsRed RNA at a level only 1/4th of that expressed
by the double-unit vector, conﬁrming the expression
results (Figure 7c). Because the dsRed RNA expressed
by the EF1a promoter (AxEFdsR) in HuH-7 cells was
480-fold higher than the direct expression of AFP
promoter, the double-unit vector utilized  1/10th of the
EF1a promoter activity on day 3. However, on day 4, the
Figure 7. Simultaneous excisional expression in HuH-7 cells using double-infection method. (a) Structure of AdVs. The representations are the same
as in Figure 1. (b) Images obtained using ﬂuorescent microscopy. (c) Fluorescence measured using a ﬂuoroscan plate reader.
Table 3. Steady-state levels of expressed dsRed RNA in HuH-7 cells
AdV
a Ratio
b
AxA2AdsR 1
AxLR16EL-AC 41
AxLR16EL+Ax-AC 10
AxEFdsR 480
AxLR16EL-AC (day 4) 91
Each experiment was performed twice to conﬁrm the reproducibility;
typical data are shown. The genome structures of the above viruses are
shown in Figures 1 and 7a.
aHuH-7 cells were infected with each AdV at a MOI of 30. In the
double infection, an MOI 15 of each virus was used.
bFor each condition, the expressed dsRed RNA measured using
real-time PCR was divided by the value obtained using the
AxA2AdsR virus.
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the double-unit vector (Table 3); because such an increase
in expression on later days was often observed in other
double-unit experiments (data not shown), this result can
likely be explained by the weak AFP promoter, since the
very small amount of expressed Cre likely required a long
time to process the target unit.
DISCUSSION
We developed a ‘double-unit’ AdV bearing an ‘excisional-
expression’ structure and established a preparation
method for this AdV. The AdV showed a high level of
expression of the target gene under the control of a
tissue/cancer-speciﬁc promoter, maintaining a very strict
speciﬁcity. We observed that (i) because the vector was a
ﬁrst-generation AdV, it could be prepared on a large-scale
without difﬁculty, and (ii) although a leak in Cre expres-
sion was observed during its preparation in E. coli and
293 cells, both problems were solved using a dominant-
negative of Cre, dnCreRY, and an shRNA against Cre,
shCreD, respectively. The complete suppression of Cre
expression in 293 cells has been especially problematic,
since AdV genome replication produces up to  100000
genome copies in each 293 cell. The key step in the pro-
duction of the double-unit AdV was the selection of a
clone lacking the AxL-AC virus (Figure 5b, lower left).
Our results showed that severe AxL-AC generation
caused by the leaky expression of Cre occurred ‘before’
the selection of a clone lacking the AxL-AC virus and
that once such a clone was obtained, problematic
deletion caused by ‘leaked’ Cre was not observed dur-
ing the second to fourth production steps. Therefore, for
the production of double-unit AdV even using
293shCreD13 cells, popular AdV-production protocols
producing a pool of AdVs after transfection cannot be
used.
As stated in the ‘Introduction’ section, this vector
system is obviously superior to the ‘double-infection’
method (3); in the latter system, two viruses must be sim-
ultaneously transduced into a single cell for expression,
and the infection of only one virus in a single cell is
useless but causes similar viral toxic effects. Therefore,
this new system will be particularly useful under diluted
conditions, such as in animal experiments for basic
research (unpublished data) as well as human gene
therapy. Here, AFP promoter was used as one example,
but obviously any tissue/cancer-speciﬁc promoter can be
used. We intentionally did not adopt a CMV or CAG
promoter, but instead used an EF1a promoter as a
potent and non-speciﬁc promoter in the target unit
because we have previously shown that the EF1a
promoter hardly induces any inﬂammation as a result of
AdV infection in an in vivo experiment, since no detectable
induction of viral pIX production occurs (29). One report
describing ‘excisional expression’ where a gene product
was expressed only after excision by Cre from a
Cre-excised circular molecule as described here has been
previously published (30), but the purpose of this previous
report was entirely different from that of the present work
because the objective of the previous study was to examine
persistent expression as a circular replicon using EB-viral
oriP and used a double infection system using
Cre-expressing AdV. Also, Yant et al. (31) reported
another type of the ‘excisional expression’, where
intron-containing transgenes were split and thus
remained inactive until an FLP-mediated circularization
restored the correct reading frame. The excision of an ex-
pression unit from the AdV genome by Cre or FLP has
occasionally been reported (for examples, 32–34).
We observed a ‘leak’ in the expression level of the
double-unit vector in an AFP-negative cell population
amounting to  1/40th of the expression level in HuH-7
cells measured using FACS as the total sum of all
cell ﬂorescence, as stated in the Results section.
While this level was very low, it was similar to the
activity of the authentic AFP promoter in HuH-7 cells
(Table 3). However, in AFP-negative cells infected
with a double-unit virus, a small number of ‘bright
cells’ highly expressing dsRed (Figure 6b, e and c, f)
were present, increasing the apparent ‘leaked’ expression
level.
Importantly, the speciﬁcity of the tissue/cancer
promoter in this vector was very strictly maintained for
a number of reasons. (i) Because the potent EF1a
promoter in the target unit is present ‘downstream’ of
the cDNA (Figure 1), an expression leak of the cDNA
via this promoter is not possible until the promoter is
translocated in front of the target cDNA by loxP recom-
bination and circularization. (ii) The loxP-combined virus
AxL-AC generated during the preparation of the
double-unit virus does not contain an expression unit
and hence does not cause non-speciﬁc expression. In
contrast, the double-infection method always generates
some stuffer-less, loxP-combined virus that causes
non-speciﬁc expression because a small amount of such
virus is generated even without Cre gene in AdV prepar-
ations, possibly through the homologous recombination
of  50nt consisting of loxPs and its surrounding
sequences (3). (iii) Though conventional viral stock
contains a small amount of circular DNA expressing the
target gene and causing non-speciﬁc expression, it can be
completely removed using a CsCl step gradient (22), since
the DNA is much heavier than the virus particle. We pre-
viously observed that a DNA molecule in the viral stock
can be ‘transfected’ into infected cells (35). (iv) The tissue-/
cancer-speciﬁc promoter is inserted at the E4 position and
is located farthest from the enhancer of a potent and
non-speciﬁc EF1a promoter inserted at the E1-insertion
site present near the left end of the genome. Therefore, the
enhancer effect of the EF1a promoter on the speciﬁc AFP
promoter is minimized. (v) A poly(A) sequence in front of
the speciﬁc AFP promoter in the switch unit (Figure 1,
upper right) suppresses non-speciﬁc transcription through
a cryptic promoter present upstream of the speciﬁc
promoter (3). And ﬁnally (vi) another poly(A) sequence
in front of the loxP-cDNA in the target unit (Figure 1,
upper left, and Figure 3) efﬁciently reduce the non-speciﬁc
expression of cDNA probably caused by upstream cryptic
promoters. We cannot argue whether the double-unit
system is better in selectivity and less ‘leaky’ than the
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further studies are needed using a more sensitive reporter
system. However, because of these reasons above, the
double-unit vector copes with high-level expression and
strict speciﬁcity.
The total length of the AdV genome used in this method
should not be more than  38kb (28). This means that the
maximum length of a speciﬁc promoter plus target cDNA
in this vector system with Bsu36I-BlpI E3 deletion (see
below) should be 3.9kb when the 14EF1a promoter is
used and 4.5kb when the 0.8-kb CMV promoter is used.
This limitation of the length does not cause a problem in
most cases. For example, because the AFP promoter used
here is 2.2kb in length, herpes thymidine-kinase cDNA
(1.2kb) or luciferase cDNA (1.7kb) can be inserted; in
fact, we constructed a double-unit AdV containing both
AFP promoter and the thymidine-kinase gene, and animal
experiments examining suicide-gene therapy are presently
underway.
The problem of the genome length limitation can be
solved using an AdV with a larger deletion in the E3
and E4 region. In the present study, AxLR14EL-AC
and AxLR16EL-AC carried a Bsu36I-BlpI E3 deletion
of 2433bp, corresponding to 28342–30775-nt positions
in the adenovirus type 5 map. The E3 region was 555-bp
shorter than the XbaI-XbaI deleted E3 (21,27) and 252-bp
longer than the BglII-BglII deleted E3 (36,37). We avoided
using the BglII-BglII deleted E3 because L4 mRNAs of
this AdV miss the L4 poly(A) sequences but use E3
poly(A) sequences, while XbaI-XbaI and Bsu36I-BplI
deleted E3 both use the authentic L4 poly(A) sequences.
Since an even shorter E3 region (27865–30995nt) (36,38)
and an E4 deletion (32825–35640nt) (38) have been
reported, the 3.9-kb limitation of the total lengths of a
speciﬁc promoter plus cDNA when using AxLR14EL-
AC could be enlarged up to 7.4kb, if these vector
constructs could be used.
Interestingly, Huyn et al. (39) recently reported an ap-
parently related but different AdV system where, as the
switch unit, a cancer-speciﬁc promoter produces a
Gal4-VP16 fusion protein and, as the target unit, a
Gal4-binding domain plus a CMV minimal promoter
is used. They claimed that their method might be
useful for visualizing cancer metastasis. A comparison
of our vector with theirs would be difﬁcult because
they conﬁrmed promoter speciﬁcity only in transfection
experiments and because a cancer-speciﬁc promoter
different from ours was used. Since our vector was
developed with the goals of not only achieving a high
expression level, but also of achieving a very low
background in applications and ensuring the safety of
gene therapy, the purposes of these studies are clearly
different.
The method described here was totally different from
that used for cancer-speciﬁc, replication-competent AdVs
(for reviews, see references 40,41) in the ﬁeld of cancer
gene therapy. Although these AdVs use cancer-speciﬁc
promoters, the adenoviruses replicate in the target cells
and produce damaging effects through adenovirus gene
expression in the target and surrounding cells. Although
it has been reported that replication of E1-dereted AdV
can be detected by Southern hybridization technique in
HeLa cells at a higher MOI (42) and in other certain
cells two weeks after infection (43), the replication
level seemed too low to inﬂuence on the results described
here.
The AdV system described here is probably useful for
studying the function of a gene product in a speciﬁc tissue
or organ. In any given tissue, several different sorts of cells
are present: for example, neurons, glia cells and vascular
endothelial cells are simultaneously present in neural
tissue. Thus, this vector would be useful for expressing a
gene selectively and efﬁciently in only one type of
cell using a cell-speciﬁc promoter. This activity could
enable novel, speciﬁc and effective therapies to be
eveloped in the ﬁeld of cancer gene therapy, and
this strategy is now being tested. Furthermore, the appli-
cation of this vector could be extended to include those
where a high expression level and a rigid speciﬁcity are
necessary.
The vector described here will be useful for many re-
searchers using tissue/cancer-speciﬁc promoters. Plasmids
suppressing Cre activity, cosmid cassettes for the construc-
tion of double-unit AdV containing trc-dnCreRY, and the
293 cell lines 293dnCreRY8 and 293shCreD13 are avail-
able from Riken Bioresource Bank (http://www.brc.riken
.go.jp/) or in collaboration basis.
SUPPLEMENTARY DATA
Supplementary data are available at NAR Online.
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